3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
10
Endocrine
2
CNS
2
Gynecologic
1
Breast
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
Temozolomide
79
Magnetic Resonance Spectroscopy
69
Specimen Handling
45
Radiotherapy
42
Bevacizumab
29
Radiosurgery
27
Cyclophosphamide
27
Radiation
20
pembrolizumab
19
Blood Specimen Collection
19
fludarabine
16
Nivolumab
16
Irinotecan
15
Carboplatin
13
Biopsy
13
Etoposide
12
Vincristine
11
Pemetrexed
11
Lomustine
11
dinutuximab
9
Surgical Procedures, Operative
9
trametinib
8
abemaciclib
8
Ipilimumab
8
Fluorodeoxyglucose F18
8
naxitamab
7
fluciclovine F-18
7
Watchful Waiting
7
Topotecan
7
Proton Therapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
belzutifan
×
CNS
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled